MRD Does Not Consistently Predict PFS Across Modern CLL Trials: Why Surrogacy Depends on Therapy, Duration, and Sample Source
Proposed section structure
For this topic, a clinically appropriate structure is: clinical context and why surrogate endpoints matter in CLL; study design and methods; main findings at the individual and trial levels; subgroup analyses by treatment class, treatment strategy, and sampling source; implications for clinical trials, regulation, and bedside practice; strengths and limitations; and a concise conclusion with evidence-based takeaways.
Highlights
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.